Compare IPSC & MRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPSC | MRBK |
|---|---|---|
| Founded | 2019 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 189.7M | 218.1M |
| IPO Year | 2021 | 2018 |
| Metric | IPSC | MRBK |
|---|---|---|
| Price | $2.33 | $19.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 3 |
| Target Price | $3.50 | ★ $20.00 |
| AVG Volume (30 Days) | ★ 976.3K | 90.9K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | N/A | ★ 2.81% |
| EPS Growth | ★ 29.07 | 25.00 |
| EPS | 0.11 | ★ 1.28 |
| Revenue | ★ $6,589,000.00 | $5,735,000.00 |
| Revenue This Year | $1,590.09 | $25.40 |
| Revenue Next Year | N/A | $8.15 |
| P/E Ratio | $20.64 | ★ $15.61 |
| Revenue Growth | ★ 194.81 | 16.38 |
| 52 Week Low | $0.34 | $11.17 |
| 52 Week High | $2.71 | $21.03 |
| Indicator | IPSC | MRBK |
|---|---|---|
| Relative Strength Index (RSI) | 62.07 | 49.78 |
| Support Level | $0.49 | $14.00 |
| Resistance Level | $2.71 | $20.86 |
| Average True Range (ATR) | 0.19 | 0.61 |
| MACD | 0.02 | -0.16 |
| Stochastic Oscillator | 79.33 | 14.74 |
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
Meridian Corp is a bank holding company. Through its banking subsidiary, it operates as a full-service, state-chartered commercial bank providing personal, business lending, and deposit services. It operates in three reportable segments including Bank, Wealth, and Mortgage. The company generates maximum revenue from the Bank segment which consists of commercial and retail banking. It generates interest income from its lending (including leasing) and investing activities and is dependent on the gathering of lower-cost deposits from its branch network or borrowed funds from other sources for funding its loans.